Related references
Note: Only part of the references are listed.Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications
Grant M. Fischer et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients
Yasuhiro Fujisawa et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2018)
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
An Overview of the Changing Landscape of Treatment for Advanced Melanoma
Chung-Shien Lee et al.
PHARMACOTHERAPY (2017)
Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab
Motoo Nomura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S. Bowyer et al.
BRITISH JOURNAL OF CANCER (2016)
Clinical Outcomes in Metastatic Uveal Melanoma Treated With PD-1 and PD-L1 Antibodies
Alain P. Algazi et al.
CANCER (2016)
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial
F. Stephen Hodi et al.
LANCET ONCOLOGY (2016)
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2016)
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura et al.
ONCOTARGET (2016)
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma
Leila Khoja et al.
CANCER MEDICINE (2016)
Nivolumab: A Review in Advanced Melanoma
Lesley J. Scott
DRUGS (2015)
BRAF and MEK inhibition in melanoma
Lesly A. Dossett et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases
Anna Maria Di Giacomo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Mechanisms of disease - Melanoma
Arlo J. Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
